Axol Bioscience Ltd. Secures $2.

Axol Bioscience Ltd. has secured $2.8 million in funding from investors. The company is a leading provider of human induced pluripotent stem cell (iPSC) technologies, specializing in the manufacture of high-performance iPSC-derived cells and the delivery of industry-leading laboratory services. With over a decade of expertise, Axol partners with global pharmaceutical companies, contract research organizations (CROs), biotechnology firms, start-ups, and academic institutions to advance the use of iPSC-based models in drug discovery and disease research.

Axol operates across five key areas, including neuroscience (covering conditions like ALS, Alzheimer’s, Huntington’s, Parkinson’s, and neuroinflammation), pain & sensation, ophthalmology (Dry-AMD, ophthal-inflammation), dermatology, and cardiovascular. The company offers scalable solutions such as iPSC banking, reprogramming, gene editing, cell manufacturing, and quality control. Its commitment lies in developing physiologically relevant in vitro systems that improve consistency and relevance in human disease modeling and compound testing, thereby aiming to close the translational gap in research.

This capital infusion will enable Axol Bioscience to accelerate its strategic growth initiatives and further enhance its operational capabilities. The company plans to use the funds to expand its scientific and service offerings, reinforcing its position as a key partner in the development of advanced iPSC-based solutions. Axol is recognized for its scientific excellence, transparent collaboration, and rigorous quality standards, with manufacturing operations certified to ISO 9001:2015.

Looking ahead, Axol Bioscience aims to continue its trajectory of innovation and expansion, driving the adoption of iPSC technologies to provide more effective tools for drug discovery and disease understanding. The company remains focused on its mission to deliver high-quality, physiologically relevant models that contribute to significant advancements in human health research globally.